Your session is about to expire
← Back to Search
mGlide Mobile Health Intervention for High Blood Pressure
N/A
Recruiting
Led By Kamakshi Lakshminarayan, MD, PhD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosis of uncontrolled HTN at the time of study enrollment (need not have had a stroke)
Stroke survivors (ischemic stroke or intra-parenchymal hemorrhage) or patients at high risk of stroke or cardiovascular disease (CVD) events (>7.5% over 10 years)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
Study Summary
This trial is testing whether a mobile health intervention can improve blood pressure control in stroke survivors and high-risk patients without stroke.
Who is the study for?
This trial is for adults with uncontrolled high blood pressure, especially those at high risk of stroke or heart disease. Participants must speak English, Spanish, or Hmong and be able to use a smartphone compatible with the BP monitoring app. Stroke survivors are also eligible. People with severe illnesses like end-stage kidney/liver disease or serious psychiatric conditions cannot join.Check my eligibility
What is being tested?
The mGlide RCT tests if using mobile health technology can better manage high blood pressure in patients at risk of cardiovascular diseases. It involves daily self-monitoring of BP via a wireless monitor and smartphone, alerting healthcare teams when readings deviate from expected levels.See study design
What are the potential side effects?
Since mGlide is a mobile health intervention focused on monitoring and managing blood pressure rather than a medication, it does not have direct side effects like drugs do. However, there may be indirect effects related to stress or anxiety from constant health monitoring.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have high blood pressure that isn't well-controlled.
Select...
I have survived a stroke or am at high risk for stroke or heart disease.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
HTN control into guideline specified range
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: mGlide InterventionExperimental Treatment1 Intervention
Participants will be educated on HTN and taught to self-monitor their BP. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice.
Group II: Clinical Care ComparisonActive Control1 Intervention
Patients will be educated similar to intervention and taught self-monitoring of BP. Then they will be asked to follow up with primary care as usual.
Find a Location
Who is running the clinical trial?
University of MinnesotaLead Sponsor
1,379 Previous Clinical Trials
1,588,051 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,835 Previous Clinical Trials
47,310,192 Total Patients Enrolled
Kamakshi Lakshminarayan, MD, PhDPrincipal InvestigatorUniversity of Minnesota
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not have severe kidney, liver disease, or any condition that limits my life to under a year.I have high blood pressure that isn't well-controlled.I am willing and able to follow all study requirements.I speak English, Spanish, or Hmong.I am unable to perform tasks required by the study.My blood pressure has been over 140 mm Hg recently.You have a serious mental illness, like schizophrenia or bipolar disorder, that could affect your ability to participate in the study.I speak English, Spanish, or Hmong.I have survived a stroke or am at high risk for stroke or heart disease.
Research Study Groups:
This trial has the following groups:- Group 1: mGlide Intervention
- Group 2: Clinical Care Comparison
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Does this research endeavor accept applicants aged 70 or above?
"Based on the requirements for enrolment, potential participants must be at least of age 18 and no older than 85."
Answered by AI
Are there currently any opportunities for individuals to enroll in the clinical trial?
"Per the information published on clinicaltrials.gov, this research trial is currently seeking participants after being initially posted on March 1st 2019 and most recently updated November 14th 2022."
Answered by AI
How many participants have signed up for this investigation?
"Affirmative. An examination of clinicaltrials.gov reveals that enrollment for this medical experiment, first posted on March 1st 2019, is still available. 450 subjects are required from a single location."
Answered by AI
Could I potentially join this research experiment?
"This clinical trial, which seeks to enroll up to 450 participants, has established that applicants must have hypertension and be between 18-85 years of age in order for their candidacy to be accepted."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger